Richard I. Fisher, MD

Richard Fisher, MD
This physician is not currently rated. Why?

Why is this doctor not rated?


To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111


President and CEO

Cancer Center Director

Robert C. Young, MD, Chair in Cancer Research

Senior Associate Dean, Lewis Katz School of Medicine, Temple University

NCCN, Board of Directors

NCCN, Non-Hodgkin's Lymphomas Panel Member


Research Program

Key Awards

Philadelphia Magazine Top Docs 2021
Medical Oncology

President, CEO and Cancer Center Director

As President and CEO, Dr. Fisher is responsible for overseeing and leading the Fox Chase Cancer Center.  He is also senior associate dean for cancer programs at the Lewis Katz School of Medicine at Temple University.

At the Fox Chase Cancer Center, Richard I. Fisher, MD, is the President, Chief Executive Officer, and Cancer Center Director, where he leads all aspects of the center. As part of the Temple University Health System, he is also senior associate dean for cancer programs.

Fisher majored in chemistry and physics at Harvard University before earning his medical degree, cum laude, from Harvard Medical School in 1970. From 1970-1972, he was an intern and resident at Massachusetts General Hospital. Highlights of his career include: immunology and oncology fellowships at the National Cancer Institute, Bethesda, MD; director of the Cardinal Bernadin Cancer Center at Loyola University Stritch School of Medicine from 1984-2001; director of the Wilmot Cancer Center at the University of Rochester School of Medicine and Dentistry (URSMD) from 2001-2013; and senior associate dean for clinical affairs and director of the Rochester Medical Faculty Group at URSMD from 2008-2011. He also served as principal investigator for a Lymphoma SPORE (Specialized Program of Research Excellence) grant.

Fisher has also held a number of important leadership positions in the oncology community including: Chair of the lymphoma committee of the Southwest Oncology Group (SWOG) from 1984-2014; deputy group chair of SWOG from 2005-2013; and Chair of the Lymphoma Research Foundation Scientific Advisory Board from 2008-2010. Other roles, honors, and awards include: Member of the Board of Scientific Advisors for the V Foundation from 2003-present; Member of the National Cancer Institute (NCI) lymphoma steering committee from 2009-2014; and Chair of the NCI Specialized Programs of Research Excellence (SPORE) review committee in 2012.

Education and Training

Educational Background

  • Fellow, Oncology, National Cancer Institute, Bethesda, MD, 1975
  • Assistant Resident, Medicine, Massachusetts General Hospital, Boston, MA, 1972
  • MD, Harvard Medical School, 1970


  • Diplomate, American Board of Internal Medicine
  • Diplomate, American Board of Internal Medicine, Subspecialty of Oncology
  • Diplomate, National Board of Medical Examiners


  • National Comprehensive Cancer Network (NCCN)
    • Cancer Center Directors
    • Non-Hodgkin's Lymphomas Panel
  • American Association for Cancer Research
  • American College of Physician Executives
  • American Medical Association
  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Association of Immunologists
  • American College of Physicians
  • Association of Subspecialty Professors
  • Central Society for Clinical Research
  • Clinical Immunology Society
  • Chicago Medical Society
  • Chicago Society of Internal Medicine
  • European Society for Medical Oncology
  • Illinois State Medical Society

Honors & Awards

  • Philadelphia Magazine Top Doctors, 2018-20
  • Best Doctors in America® , 1999-2016, 2019-2020
  • Member, Lymphoma Steering Committee, National Cancer Institute (NCI), 2009-present
  • Member, Board of Scientific Advisors, V Foundation, 2003-present
  • Distinction and HOPE Award, American Cancer Society, 2010
  • Chair, Review Committee, NCI Specialized Programs of Research Excellence (SPORE), 2010
  • Team Science Award, Cytebrine Working Group, 2010
  • Harold Amos Fellow, Dean’s Council, Harvard Medical School, 2010
  • Freundlich Leadership Award, Lymphoma Research Foundation, 2009
  • Davey Memorial Award for Outstanding Cancer Research, University of Rochester Medical Center, 2006
  • Grinberg/Wisch Endowed Visiting Lectureship in Hematology/Oncology, Mount Sinai School of Medicine, 2005
  • Derrick Crowther Lecturer, Cologne, Germany, 2001
  • Member, Honorary Medical Board, Lymphoma Research Foundation of America, 2000-2001
Patient Stories

Brian Kozera


Brian Kozera


As my arms sliced through the surface of the cool, turquoise, waters of Austria’s Lake Wörthersee, I couldn’t believe that this moment had arrived. Just two years earlier, in 2014, my world was turned upside down when I was diagnosed with cancer.

Research Profile

Research Program

Research Interests

  • Development of novel treatments for non-Hodgkin’s lymphoma and Hodgkin disease
  • Development of prognostic markers for non-Hodgkin’s lymphoma and Hodgkin disease
  • Understanding the immunologic response to non-Hodgkin’s lymphoma and Hodgkin disease

Selected Publications

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1801994, 2019.

Blanke CD, Crowley J, Baker LH, Fisher RI. In Memoriam: Charles A. Coltman, 1930 to 2018. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1900270, 2019.

Press OW, Li HL, Schoder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology, 34(17):2020-+, 2016. PubMed

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. New England Journal of Medicine, 369(18):1681-90, 2013. 

Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology, 32(27):3048-+, 2014. PubMed

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao WM, Zhang MZ, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu XL, Powell J, Yang YD, Xu WH, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 490(7418):116-20, 2012.  PubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32(27):3059-+, 2014.  PubMed

Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Kohlhammer, H., Xu, W.,Yang, Y., Zhao, H., Shaffer, A.L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Muller-Hermelink, H.K., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., and Staudt, L.M. Oncogenically Active MYDSS Mutations in Human Lymphoma. Nature. 470:115-119, 2011.   PubMed

 Davis, R.E; Ngo, V.N; Lenz, G; Tolar, P.; Young, R.; Romesser, P.B.; Kohlhammer, H.; Lamy, L; Zhao, H.; Yang, Y.; Xu, W.; Shaffer, A.L.; Wright, G.; Xiao, W.; Powell, J.; Jiang, J.; Thomas, C.J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Rimsza, L.M.; Campo, E.; Jaffe, E.S.; Delabie, J.; Smeland, E.B.; Fisher, R.I.; Braziel, R.M.; Tubbs, R.R.; Cook, J.R.; Weisenburger, D.D.; Chan, W.C.; Pierce, S.K. and Staudt, L.M. Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma. Nature 463:88-92, 2010. PMC2845535    PubMed

Lenz, G.; Wright, G.; Dave, S.S; Xiao, W.; Powell, J.; Zhao, H.; Xu, W.; Tan, B.; Goldschmidt, N.; Iqbal, J.; Vose, J.; Bast, M.; Fu, K.; Weisenburger, D.D.; Greiner, T.C.; Armitage, J.O.; Kyle, A.; May, L.; Gascoyne, R.D.; Connors, J.M.; Troen, G.; Holte, H.; Kvaloy, S.; Dierickx, D.; Verhoef, G.; Delabie, J.; Smeland, E.B.; Jares, P.; Martinez, A.; Lopez-Guillermo, A.; Montserrat, E.; Campo, E.; Braziel, R.M.; Miller, T.P.; Rimsza, L.M.; Cook, J.; Pohlman, B.; Sweetenham, J.; Tubbs, R.R.; Fisher, R.I.; Hartmann, E.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Wrench, D.; Lister, T.A.; Jaffe, E.S.; Wilson, W.H.; Chan, W.C., and Staudt, L.M. for the Lymphoma/Leukemia Molecular Profiling Project. Stromal Gene Signatures in Large B Cell Lymphoma. New England Journal of Medicine. 359: 2313-2323, 2008.    PubMed

Lenz, G.; Wright, G.W.; Emre, T.; Kohlhammer, H.; Dave, S.S.; Davis, R.E.; Carty, S.; Lam, L.T.; Shaffer, A.L.; Xiao, W.; Powell, J.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Campo, E.; Jaffe, E.S.; Delabie, J.; Smeland, E.B.; Rimsza, L.M.; Fisher, R.I.; Weisenburger, D.D.; Chan, W.C., and Staudt, L.M. Gene Expression Subtypes of Diffuse Large B cell lymphoma Arise by Distinct Genetic Pathways. Proceedings of the National Academy of Science. 105:135 20-5, 2008    PubMed

Lenz, G.; Davis, R.E.; Ngo, V. U.; Lam, L.; George, T.C.; Wright, G.W.; Dave, S.S.; Zhao, H.; Xu, W.; Rosenwald, A.; Ott, G.; Muller-Hermelink, H.K.; Gascoyne, R.D.; Connors, J.M.; Rimsza, L.M.; Campo, E.; Jaffe, E.S.; Delabie, J.; Smeland, E.B.; Fisher, R.I.; Chan, W.C. and Staudt, L.M. for the Leukemia Lymphoma Molecular Profiling Project. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science. 319: 1676-1679, 2008. 

Sandeep, D.S., Kai, F., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Hermelink, H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C., Staudt, L.M.: Molecular Diagnosis of Burkitt Lymphoma. N. Engl. J. Med. 354:2431-2442, 2006.

 Dave, S.S., Wright, G., Tan, B, Rosenwald, A., Gascoyne, R.D., Chan. W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H. , Delabie, J., Connors, J.M., Lansdorp, P., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L.,Powell, J., Zhaol, H., Goldschmidt, N., Chiorazzi, M., Staudt, L.M. Length of survival following the diagnosis of follicular lymphoma is predicted by molecular features of non-malignant tumor infiltrating immune cells. N. Engl. J. Med 351:2159-2169, 2004.

 Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Wing C., Chan, W.C., Zhao, H., Haioun, C., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H.K., Connors, J.M., Braziel, R., Grogan, T.M., Fisher, R.I., Miller, T.P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., and Staudt, L.M. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198:851-862, 2003. PMC2194208    PubMed

Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Muller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrickson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J. and Staudt, L.M. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 3:185-197, 2003.     PubMed

Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.N., Konrad Muller-Hermeliuk, H., Smeland, E.R., and Staudt, L.M. The use of molecular profiling to predict survival after chemotherapy of diffuse large B-cell lymphomas. N. Engl. J. Med. 346:1937-1947, 2002.    PubMed

Hasenclever, D., Diehl, V., Armitage, J.O., Assouline, D., Bjorkholm, M., Brusamolino, E., Canellos, G.P., Carde, P., Crowther, D., Cunningham, D., Eghbali, H., Ferme, C., Fisher, R.I., Glick, H.J., Glimelius, B., Gobbi, P.G., Holte, H., Horning, S.J., Lister, T.A., Longo, D.L., Mandelli, F., Polliack, A., Proctor, S.J., Specht, L., Sweetenham, J.W., Hudson, G.V.: A Prognostic Score for Advanced Hodgkin’s Disease. N. Engl. J.Med. 339:1506-1514, 1998.

Miller, T.P., Dahlberg, S., Cassady, J.R., Adelstein,, D.J., Spier, C.M., Grogan, T.M., LeBlanc, M., Carlin, S., Chase, E., and Fisher, R.I.: A randomized trial comparing chemotherapy alone to chemotherapy followed by radiotherapy for localized intermediate and high grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 339:21-25, 1998.  

Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonnadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffer, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S.J., Engelhard, M., Fisher, R.I., Insselbrecht, C., Horning, S.J., Lepage, E., Lister, A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez, W.S., and Yeap, B.Y: Development of a predictive model for aggressive lymphoma: The international non-Hodgkin's lymphoma prognostic factors project. N. Engl. J. Med. 329:987-994, 1993. 

Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A., and Miller, T.P.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1002-1006, 1993.   PubMed

Additional Publications


Connect with Fox Chase